ArticlePharmacoEconomics - open2021

A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile.

Manuel Antonio Espinoza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.